High proliferation is associated with inferior outcome in male breast cancer patients.
Assessment of proliferation is important in female breast cancer and individual treatment decisions are based upon its results, especially in the luminal subgroups. Gene expression analyses fail to group male breast cancer into the intrinsic subgroups previously established in female breast cancer. Even though proliferation has been shown to divide male breast cancer into molecular subgroups with different prognoses, the clinical importance of proliferation markers has not yet been elucidated. Previous studies in male breast cancer have demonstrated contradictory results regarding the prognostic impact of histological grade and Ki-67, parameters strongly associated with proliferation. The aim of the present project was to study proliferation in male breast cancer by assessing other proliferation-related markers viz. cyclins A, B, D1 and mitotic count. A total of 197 male breast cancer cases with accessible paraffin-embedded material and outcome data were investigated. Immunohistochemical stainings were performed on tissue microarrays. Kaplan-Meier estimates and the Cox proportional regression models were used for survival analyses with breast cancer death as the event. The subset of patients with high expression of cyclin A (hazard ratio (HR) 3.7; P=0.001) and B (HR 2.7; P=0.02) demonstrated a poorer survival. Furthermore, high mitotic count was associated with an increased risk of breast cancer death (HR 2.5; P=0.01). In contrast, cyclin D1 overexpression was predictive of better breast cancer survival (HR 0.3; P=0.001). In conclusion, high levels of cyclin A and B expression and an elevated mitotic count result in a two to threefold higher risk for breast cancer death, whereas cyclin D1 overexpression halves the risk. The clinical utility of these proliferation markers needs further elucidation.
Department of Oncology, Center for Clinical Research, Västmanland County Hospital, Västerås, Sweden.
Cecilia
C
Nilsson
Anthoula
A
Koliadi
Ida
I
Johansson
Cecilia
C
Ahlin
Sten
S
Thorstenson
Leif
L
Bergkvist
Ingrid
I
Hedenfalk
Marie-Louise
ML
Fjällskog
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D018567:Breast Neoplasms, Male / Q000378:metabolism / Q000401:mortality* / Q000473:pathology*; D049109:Cell Proliferation; D019925:Cyclin A / Q000032:analysis / Q000096:biosynthesis; D019926:Cyclin B / Q000032:analysis / Q000096:biosynthesis; D019938:Cyclin D1 / Q000032:analysis / Q000096:biosynthesis; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D008940:Mitotic Index; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D046888:Tissue Array Analysis; D055815:Young Adult
D014408:Biomarkers, Tumor; D019925:Cyclin A; D019926:Cyclin B; D019938:Cyclin D1